دورية أكاديمية
أعرض في EDS

A genome-wide enrichment screen identifies NUMA1-loss as a resistance mechanism against mitotic cell-death induced by BMI1 inhibition.

التفاصيل البيبلوغرافية
العنوان: A genome-wide enrichment screen identifies NUMA1-loss as a resistance mechanism against mitotic cell-death induced by BMI1 inhibition.
المؤلفون: Gisler S; Division of Molecular Genetics, Oncode and The Netherlands Cancer Institute, Amsterdam, The Netherlands., Maia ARR; Division of Cell Biology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Chandrasekaran G; Division of Molecular Genetics, Oncode and The Netherlands Cancer Institute, Amsterdam, The Netherlands., Kopparam J; Division of Molecular Genetics, Oncode and The Netherlands Cancer Institute, Amsterdam, The Netherlands., van Lohuizen M; Division of Molecular Genetics, Oncode and The Netherlands Cancer Institute, Amsterdam, The Netherlands.
المصدر: PloS one [PLoS One] 2020 Apr 28; Vol. 15 (4), pp. e0227592. Date of Electronic Publication: 2020 Apr 28 (Print Publication: 2020).
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE
أسماء مطبوعة: Original Publication: San Francisco, CA : Public Library of Science
مواضيع طبية MeSH: Antineoplastic Agents/*pharmacology , Carcinogenesis/*genetics , Cell Cycle Proteins/*genetics , Drug Resistance, Neoplasm/*genetics , Neoplasms/*genetics , Polycomb Repressive Complex 1/*metabolism, Antineoplastic Agents/therapeutic use ; Apoptosis/drug effects ; Apoptosis/genetics ; CRISPR-Cas Systems/genetics ; Carcinogenesis/drug effects ; Cell Line, Tumor ; Cell Proliferation/drug effects ; Cell Proliferation/genetics ; Gene Expression Regulation, Neoplastic ; Gene Knockdown Techniques ; Gene Knockout Techniques ; Humans ; M Phase Cell Cycle Checkpoints/drug effects ; Mutation ; Neoplasms/drug therapy ; Neoplasms/pathology ; Polycomb Repressive Complex 1/antagonists & inhibitors ; Polycomb Repressive Complex 1/genetics ; RNA, Small Interfering/metabolism
مستخلص: BMI1 is a core protein of the polycomb repressive complex 1 (PRC1) that is overexpressed in several cancer types, making it a promising target for cancer therapies. However, the underlying mechanisms and interactions associated with BMI1-induced tumorigenesis are often context-dependent and complex. Here, we performed a drug resistance screen on mutagenized human haploid HAP1 cells treated with BMI1 inhibitor PTC-318 to find new genetic and mechanistic features associated with BMI1-dependent cancer cell proliferation. Our screen identified NUMA1-mutations as the most significant inducer of PTC-318 cell death resistance. Independent validations on NUMA1-proficient HAP1 and non-small cell lung cancer cell lines exposed to BMI1 inhibition by PTC-318 or BMI1 knockdown resulted in cell death following mitotic arrest. Interestingly, cells with CRISPR-Cas9 derived NUMA1 knockout also showed a mitotic arrest phenotype following BMI1 inhibition but, contrary to cells with wildtype NUMA1, these cells were resistant to BMI1-dependent cell death. The current study brings new insights to BMI1 inhibition-induced mitotic lethality in cancer cells and presents a previously unknown role of NUMA1 in this process.
Competing Interests: The authors have declared that no competing interests exist.
References: PLoS One. 2019 Feb 12;14(2):e0212053. (PMID: 30753225)
EMBO J. 2015 Dec 14;34(24):2993-3008. (PMID: 26530471)
Nature. 2011 Aug 24;477(7364):340-3. (PMID: 21866103)
Cell Stem Cell. 2010 Dec 3;7(6):682-93. (PMID: 21112563)
Nat Cell Biol. 2001 Dec;3(12):1069-75. (PMID: 11781568)
Medicine (Baltimore). 2017 Jun;96(26):e7346. (PMID: 28658153)
Mol Biol Cell. 2007 Feb;18(2):348-61. (PMID: 17108325)
Blood. 2010 May 20;115(20):4039-42. (PMID: 20233975)
Oncol Rep. 2017 Apr;37(4):2382-2390. (PMID: 28260023)
Oncotarget. 2016 Jun 14;7(24):37192-37204. (PMID: 27177084)
Cancer Lett. 2018 Jul 10;426:4-13. (PMID: 29626519)
J Cancer Res Clin Oncol. 2008 Sep;134(9):1037-42. (PMID: 18264721)
PLoS One. 2013 Jul 08;8(7):e70339. (PMID: 23861985)
Nucleic Acids Res. 2014 Jun;42(10):6365-79. (PMID: 24753406)
Nat Cell Biol. 2009 Apr;11(4):365-74. (PMID: 19337318)
Cancer Res. 2008 Nov 15;68(22):9125-30. (PMID: 19010882)
Oncogene. 2006 Jul 20;25(31):4370-5. (PMID: 16501599)
Ann Oncol. 2015 Oct;26(10):2180-92. (PMID: 26153498)
Oncogene. 2015 Jun 4;34(23):3063-75. (PMID: 25088203)
Cell Death Differ. 2011 Nov;18(11):1771-9. (PMID: 21546904)
Genes Dev. 2005 Jun 15;19(12):1438-43. (PMID: 15964995)
EMBO Rep. 2004 Jan;5(1):97-103. (PMID: 14710193)
Curr Biol. 2008 Jul 22;18(14):1094-9. (PMID: 18635350)
Nat Cell Biol. 2013 Jul;15(7):846-52. (PMID: 23728424)
Nature. 2017 Jan 19;541(7637):412-416. (PMID: 28077878)
Mol Cell Biol. 2013 Jun;33(12):2447-57. (PMID: 23589328)
BMC Cancer. 2014 Oct 28;14:785. (PMID: 25348805)
J Cell Sci. 2009 Aug 1;122(Pt 15):2579-85. (PMID: 19625502)
Cell. 1991 May 31;65(5):753-63. (PMID: 1904009)
Nature. 1994 May 26;369(6478):321-3. (PMID: 8183370)
Mol Cancer Res. 2009 Dec;7(12):1937-45. (PMID: 19934271)
Nat Med. 2014 Jan;20(1):29-36. (PMID: 24292392)
Science. 2013 Apr 26;340(6131):479-83. (PMID: 23519211)
Trends Cell Biol. 2010 Apr;20(4):214-22. (PMID: 20137953)
Science. 2014 Jun 27;344(6191):1506-10. (PMID: 24970085)
PLoS One. 2011 Feb 02;6(2):e14648. (PMID: 21311599)
Chemotherapy. 2011;57(6):488-96. (PMID: 22248802)
Cancer Cell Int. 2017 Nov 21;17:107. (PMID: 29200967)
Nature. 2005 Sep 8;437(7056):275-80. (PMID: 16094321)
Cancer Cell. 2010 Oct 19;18(4):316-28. (PMID: 20951942)
Proc Natl Acad Sci U S A. 2008 Nov 25;105(47):18507-12. (PMID: 19017805)
Oncotarget. 2018 Jun 19;9(47):28547-28560. (PMID: 29983879)
J Cell Sci. 1995 Feb;108 ( Pt 2):621-33. (PMID: 7769006)
Science. 2009 Nov 27;326(5957):1231-5. (PMID: 19965467)
J Neurosci. 2009 Jul 15;29(28):8884-96. (PMID: 19605626)
Cell. 1991 May 31;65(5):737-52. (PMID: 1904008)
Genes Dev. 1999 Oct 15;13(20):2678-90. (PMID: 10541554)
Cell Biol Int. 2014 Jun;38(6):737-46. (PMID: 24677263)
Nature. 1999 Jan 14;397(6715):164-8. (PMID: 9923679)
Cancer Biol Ther. 2015;16(5):756-63. (PMID: 25880371)
Stem Cells. 2013 Sep;31(9):1910-20. (PMID: 23712803)
Dev Cell. 2007 Jul;13(1):29-42. (PMID: 17609108)
Cancer Res. 2009 Dec 1;69(23):9090-5. (PMID: 19903841)
المشرفين على المادة: 0 (Antineoplastic Agents)
0 (BMI1 protein, human)
0 (Cell Cycle Proteins)
0 (NUMA1 protein, human)
0 (RNA, Small Interfering)
EC 2.3.2.27 (Polycomb Repressive Complex 1)
تواريخ الأحداث: Date Created: 20200429 Date Completed: 20200706 Latest Revision: 20231113
رمز التحديث: 20231113
مُعرف محوري في PubMed: PMC7188281
DOI: 10.1371/journal.pone.0227592
PMID: 32343689
قاعدة البيانات: MEDLINE
الوصف
تدمد:1932-6203
DOI:10.1371/journal.pone.0227592